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specific homeodomain protein that plays an impor- 
tant rote in tung and thyroid morphogenesis. Mice 
with complete TTF1 deficiency Lack thyroid, Lungs, 
pituitary, with defects in the ventral forebrain. 
Results: A heterozygous deletion of 2bp from 
exon 2 was found (183 detAC), Leading to an eLon- 
gated missense protein Lacking the homeobox do- 
main. TTF-1 controls the expression of an array of 
genes including BMP-4, surfactant proteins, among 
others. InterestingLy, tow expression of the tu- 
mor necrosis factor receptor family member TACI 
had been found in the patient's peripheral blood 
monocytes. Mutations in TACI had been recently 
reported to cause IgA deficiency. 
Conclusions: It is apparent that TTF1 has a signif- 
icant regulatory rote in immunity, and appears to 
be involved in IgA and possibly IgG production. This 
rare autosoma[ dominant disorder is a paradigm for 
complex regulation of immune and somatic genes 
by a single transcription factor. 
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Introduction: Chronic granuLomatous disease (CGD), 
a genetic disorder of phagocyte NADPH oxidase, 
predisposes to infections and inflammatory com- 
plications, including severe colitis. Infliximab, a 
chimeric monocLonaL antibody to tumor necrosis 
factor-aLpha (TNF~), closes fistulas and induces and 
maintains remission in inflammatory bowel disease 
(IBD). We have used infliximab for fistuLizing and 
active IBD in 3 patients with CGD. 
Methods: Patients had progressed espite therapy 
with steroids, ASA derivatives, and antimicrobiaLs. 
BaseLine radioLogic and endoscopic evaluations pre- 
ceded infliximab at a dose of 5 mg/kg IV every 4 
weeks. ALL patients received 6-MP, prednisone and 
a saLicyLic acid derivative, as weLL as TMP/SMX and 
itraconazoLe or voriconazoLe prophylaxis. 
Results: Patient 1, a 16 year old girl with p47phox 
deficient CGD and colitis, presented with a painful 
rectovagina[ fistula. Her fistula closed and symp- 
toms resolved on infliximab. Around her 8th dose 
of infliximab, she developed Burkholderia cepacia 
pneumonia. Antibacterial therapy was successfuL. 
Patient 2 is a 20 year old man with gp91phox 
deficient CGD who had Long standing history of pe- 
riana[ abscess and fistulae along with uncontroLLed 
IBD. His symptoms and fistulae regressed on inflix- 
imab. After the 5th dose, he developed a symp- 
tomatic perirecta[ abscess, possibly due to closure 
of the draining fistula, with associated inguinal [ym- 
phadenitis. Lymph node culture grew Candida lusi- 
taniae. Patient 3 is a 17 year old boy with gp91 phox 
deficient CGD who had a rectovesica[ fistula and 
active IBD. Infliximab remitted symptoms and re- 
duced the fistula. After the 3rd dose he developed 
Burkholderia gladioli sepsis, which responded to 
standard therapy. A diverting coLostomy and 2 more 
doses of infliximab ted to closure of the fistula. 
After the 5th dose, an asymptomatic Paecilomyces 
variotti pneumonia Led to cessation of infliximab. 
Conclusions: We have used infliximab in patients 
with CGD for severe fistuLizing IBD. In 3 patients 
and 18 infusions, we encountered the typical CGD 
pathogens, Burkholderia nd Paecilomyces, but not 
other opportunistic pathogens, such as mycobacte- 
ria. Infliximab was highly effective in the treatment 
of refractory CGD associated colitis. However, we 
noted an increased rate of typical CGD infections. 
TNF blockade in CGD should be used with caution 
and with extremely close surveiLLance for infection. 
